Quoin Pharmaceuticals Q3 2026 Earnings Date & Estimates

Quoin Pharmaceuticals (NASDAQ:QNRX) Ltd. (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s programs are primarily designed to address disorders affecting the skin and other tissues, with an emphasis on topical drug-delivery technologies.

Quoin’s lead product candidate, QRX003, is an investigational topical lotion being developed for Netherton syndrome, a rare genetic skin disorder associated with impaired skin barrier function and inflammation. The company is also developing QRX004, an investigational topical treatment for recessive dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and blistering.

Quoin Pharmaceuticals is headquartered in the United States and operates as an international biotechnology company serving the rare-disease treatment market. The company was formerly known as Cellect Biotechnology Ltd. and adopted the Quoin Pharmaceuticals name as it shifted its focus toward rare-disease therapeutics. Michael Myers serves as the company’s chief executive officer.